Novo Nordisk faces slowing demand, rising competition, and CEO transition. Learn about challenges impacting its growth and ...

Shares of Novo Nordisk ( NVO 2.48%) are falling this week, down 33% as of 3:27 p.m. ET on Friday. The drop comes as the S&P ...

The introduction of GLP-1s for weight loss has been a dysfunctional mess, thanks to pharmaceutical companies, insurance plans ...

The prices for Novo and Lilly’s GLP-1s are certainly much higher than those for compounded alternatives, which have generally been priced at around $200 for a month’s supply, according to Hims ...

Cigna has announced plans to launch a new specialized GLP-1 pharmacy called ENGUIDE from next month, as the obesity drug class popularized by Novo Nordisk and Eli Lilly becomes a key component of ...

If you're looking for a top healthcare stock to buy that has much more upside in GLP-1, then going with Eli Lilly or Novo Nordisk can make much more sense at this stage.

According to analysts, net discounts for employers on list prices range from 30% to 50%. Zepbound lists at $1,100 with a $725 net price; Wegovy lists at $1,350/month but averaged $616 net in March.

Brian Evanko, Cigna’s president and chief operating officer, noted that the U.S. market in GLP-1 medications, used to treat diabetes and weight loss management, will reach $100 billion by 2030.